Â
BioCryst Pharmmaceuticals Inc. shares are up 32 percent to $5.60, on premarket volume of more than 100,000 shares. The company posted positive results from two Phase III studies of intravenous peramivir in patients with seasonal influenza. The studies were sponsored by BioCryst’s partner Shionogi & Co and conducted during the 2008-2009 influenza season. — Mike Tarsala.
No comments:
Post a Comment